An engineered SARS-CoV-2 receptor-binding domain produced in Pichia pastoris as a candidate vaccine antigenMiladys Limonta‐Fernández, Gerardo Guillén, Yassel Ramos-Gómez et al.|New Biotechnology|2022Cited by 58
The SARS-CoV-2 receptor-binding domain expressed in Pichia pastoris as a candidate vaccine antigenMiladys Limonta‐Fernández, Gerardo Guillén, Glay Chinea-Santiago et al.|medRxiv|2021Cited by 19
Safety and Immunogenicity of the Intranasal Vaccine Candidate Mambisa and the Intramuscular Vaccine Abdala Used as Booster Doses for COVID-19 Convalescents: A Randomized Phase 1–2 Clinical TrialGilda Lemos, Gerardo Guillén, Yinet Barrese-Pérez et al.|Vaccines|2024Cited by 5
A narrative review on Epidermal Growth Factor (EGF) intralesional infiltrations for diabetic complex wounds: The rational of an innovative delivery routeJorge Berlanga‐Acosta, Gerardo Guillén, Jose Fernandez-Montequin et al.|Vascular Diseases and Therapeutics|2022Cited by 2
Safety and Immunogenicity of the Intranasal Vaccine Candidate Mambisa and the Intramuscular Vaccine Abdala Used as Booster Doses for COVID-19 Convalescents: A Randomized Phase 1–2 Clinical TrialGilda Lemos, Gerardo Guillén, Yinet Barrese-Pérez et al.|Preprints.org|2024Cited by 2